Women in combat fight for more than just their lives. Being good isn’t always good enough, but these women battle for country, team and heart with guts and passion. Legendary Army medevac pilot Sarah Benson and U.S. Navy Seal Ethan Quinn team up in Risk Taker. Sarah and Ethan’s story continues in the heart pounding sequel Degree of Risk. Don’t miss the excitement of New York Times bestselling author Lindsay McKenna’s Shadow Warrior series. http://www.LindsayMcKenna.com Romantic suspense, military suspense
Only 1 minicar out of 11 tested achieves an acceptable rating in the Insurance Institute for Highway Safety's small overlap front crash test, making these tiny vehicles the worst performing group of any evaluated so far.
The Chevrolet Spark's acceptable rating in the test, along with good ratings in the Institute's four other crashworthiness evaluations, earns the new minicar a 2014 TOP SAFETY PICK award. The Spark was among the initial award winners announced in December. The new small overlap test results for the rest of the minicar group mean that no other models in this size category join the Spark in the winner's circle yet.
The countdown to the Sochi 2014 Olympic Winter Games is on, and Pop-Tarts® has partnered with U.S. Olympic hopefuls and freestyle skiers Torin Yater-Wallace and Maggie Voisin to put a Crazy Good™ spin on the competition. Eighteen-year-old Torin was nominated to the U.S. Men’s Freeskiing Team this week, and is a rising star heading into the Sochi Games. Maggie was also nominated this week to the U.S. Women’s Freeskiing Team – making her the youngest U.S. Winter Olympic hopeful at 15 years old since 1972. With the help of Pop-Tarts, they’re giving teens an exclusive look inside their Crazy Good Winter adventures.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65330-kellogg-pop-tarts-skiiers-torin-yater-wallace-maggie-voisin-sochi-olympics
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory―to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today’s laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65931-accelrys-capture-drives-next-generation-mobility-in-the-laboratory
T. Rowe Price’s 2014 Parents, Kids & Money Survey revealed that parents’ behaviors are often at odds with their concerns about setting a good financial example for their kids.
T. Rowe Price encourages parents to invest in their kids’ futures by talking to them about money matters weekly. To help, the firm created MoneyConfidentKids.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65887-money-confident-kids-presented-by-t-rowe-price/
The Chevrolet Equinox and its twin, the GMC Terrain, are the only midsize SUVs out of nine evaluated to earn a good rating in the Insurance Institute for Highway Safety’s small overlap front crash test, which continues to challenge manufacturers more than a year and a half after its introduction.
The Equinox and the Terrain qualify for the Institute’s highest award for 2014, TOP SAFETY PICK+. The Toyota Highlander, a midsize SUV whose acceptable small overlap rating was announced in December, also qualifies. The award is given to vehicles with a good or acceptable small overlap rating, good ratings in four other occupant protection tests, and a rating of basic or higher for front crash prevention.
Three other midsize SUVs in the test group rate poor for small overlap protection, and three are marginal.
There’s a dance that goes on between mothers and their newborns: the initiation of relationship and communication. However, current culturally driven health and child care practices are interrupting the dance and causing more harm than good. As a result, parents, especially first time parents, often require a great deal of education and support.
Dr. Barbara Morrison (DrBarb) is a certified nurse midwife dedicated to advocating, educating and inspiring healthcare reform for newborns and their families. As the founder and CEO of DrBarbCNM, LLC (http://www.DrBarbCNM.com), DrBarb is among the leading advocates of Kangaroo Care, the method of holding a newborn or infant skin-to skin, chest-to-chest to strengthen the bond between parent and child and to encourage breastfeeding and mental, social and physical development.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62882-close-up-talk-radio-recognizes-dr-barbara-morrison
The cost of long term care continues rising at a rate outpacing inflation creating significant financial planning challenges for the nearly 12 million Americans currently in need of long term care services. According to the Genworth (NYSE: GNW) 2014 Cost of Care Survey released today, the cost of receiving in-home care continues to rise, though at a more moderate rate of growth. This is good news for consumers as almost three quarters of people needing long term care prefer receiving it in their homes, according to Genworth’s extensive claims data (Long term care claims Experience Data for Genworth Life Insurance Company and affiliates – December 1974-June 30, 2013).
To view the Multimedia News Release, go to http://www.multivu.com/mnr/70631511-genworth-2014-cost-of-care-survey-results
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
